Atea Pharmaceuticals (AVIR) to Release Quarterly Earnings on Thursday

Atea Pharmaceuticals (NASDAQ:AVIR) is anticipated to release its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Atea Pharmaceuticals to post earnings of ($0.49) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Friday, March 6, 2026 at 4:00 PM ET.

Atea Pharmaceuticals Stock Performance

NASDAQ AVIR opened at $4.62 on Thursday. Atea Pharmaceuticals has a fifty-two week low of $2.45 and a fifty-two week high of $4.80. The stock has a 50 day simple moving average of $3.87 and a two-hundred day simple moving average of $3.43. The stock has a market cap of $360.96 million, a P/E ratio of -2.61 and a beta of 0.24.

Hedge Funds Weigh In On Atea Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Opaleye Management Inc. bought a new stake in shares of Atea Pharmaceuticals during the 4th quarter valued at $642,000. Millennium Management LLC increased its stake in shares of Atea Pharmaceuticals by 43.3% in the 4th quarter. Millennium Management LLC now owns 698,156 shares of the company’s stock worth $2,492,000 after acquiring an additional 210,933 shares in the last quarter. Bridgeway Capital Management LLC lifted its position in Atea Pharmaceuticals by 3.7% during the 4th quarter. Bridgeway Capital Management LLC now owns 148,400 shares of the company’s stock valued at $530,000 after acquiring an additional 5,300 shares during the period. Schonfeld Strategic Advisors LLC bought a new stake in Atea Pharmaceuticals during the fourth quarter worth about $164,000. Finally, Jump Financial LLC boosted its stake in Atea Pharmaceuticals by 36.5% during the fourth quarter. Jump Financial LLC now owns 19,113 shares of the company’s stock worth $68,000 after acquiring an additional 5,106 shares in the last quarter. Institutional investors own 86.67% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AVIR. Evercore raised Atea Pharmaceuticals to a “strong-buy” rating in a research note on Friday, November 28th. Weiss Ratings restated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Atea Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $6.00.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.